Everest Medicines Limited

1952.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$31.10

−HK$0.34 · -1.08%

Aug 24, 4:08 PM HKT

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Yongqing Luo
Listed since: Oct 9, 2020
Employees: 812

Market position

Day range

Current HK$31.10

HK$30.02HK$33.50

52-week range

Current HK$31.10

HK$22.70HK$75.15

Open: HK$32.72
Previous close: HK$31.44
Volume: 20.98M; 4.2× average
Average volume: 5M; Average daily volume
Market cap: 10.93B HKD
Beta: 1.54; Market reference 1
50-day average: HK$26.6944; +16.50% above average
200-day average: HK$35.6478; -12.76% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 9.31B CNY
P/E (TTM): -168.81×
P/B (TTM): 1.52×
P/S (TTM): 3.89×
EV / EBITDA: -44.07×
Earnings yield: -2.68%
Free cash flow yield: -1.55%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 69.83%
Operating margin: -5.31%
Net margin: -2.24%
Return on equity: -5.61%
Return on assets: -4.35%
Return on invested capital: -3.16%

Financial health

Debt / equity: 0.38×
Current ratio: 4.89×

1952.HK peers

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 1952.HK

research.disclaimer